Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

History

Cingulate Therapeutics was founded in 2019 with the goal of developing novel, proprietary biotherapeutics for the treatment of emotional and mental disorders. The company has developed novel therapeutic approaches by applying insights from cognitive neuroscience and epigenetics research. The company is based in the San Francisco Bay Area and is backed by venture capital investors.

Mission

Cingulate Therapeutics is dedicated to developing novel therapeutic approaches that improve the lives of people suffering from emotional and mental disorders.

Vision

Cingulate Therapeutics aims to become a global leader in the development of innovative therapeutics for the treatment of emotional and mental disorders.

Key Team

Mr. Craig S. Gilgallon Esq. (Exec. VP, Gen. Counsel & Board Sec.)

Dr. Raul R. Silva M.D. (Exec. VP & Chief Science Officer)

Thomas Dalton (Head of Investor & PR)

Dr. Matthew N. Brams M.D. (Exec. VP & Chief Medical Officer)

Recognition and Awards

Cingulate Therapeutics has been recognized as a promising, early-stage biotechnology company and has received awards from numerous organizations, including the National Institutes of Health.

References

https://in.investing.com/equities/cingulate

https://finance.yahoo.com/quote/CING/profile?p=CING

https://www.crunchbase.com/organization/cingulate-therapeutics

https://www.cingulate.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Dr. Shane J. Schaffer Pharm.D., PharmD (CEO & Chairman)

Mr. Louis G. Van Horn CPA, M.B.A. (Exec. VP & CFO)

Dr. Laurie A. Myers M.B.A., Ph.D. (Exec. VP & COO)

Products/ Services

Biotechnology, Health Care, Medical

Number of Employees

0 - 50

Headquarters

Morristown, New Jersey, United States

Established

2012

Company Registration

SEC CIK number: 0001862150

Traded as

NASDAQ:CING

Social Media

URL

https://www.cingulate.com

Last updated: Tue Feb 25 2025

We value your privacy

Cingulate Therapeutics

Table of content

Summary